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Abstract 
Background: Cardiovascular disease (CVD) is the leading cause of deaths globally, with greatest premature mortal‑
ity in the low‑ and middle‑income countries (LMIC). Many of these countries, especially in sub‑Saharan Africa, have 
significant budget constraints. The need for current evidence on which interventions offer good value for money to 
stem this CVD epidemic motivates this study.
Methods: In this systematic review, we included studies reporting full economic evaluations of individual and 
population‑based interventions (pharmacologic and non‑pharmacologic), for primary and secondary prevention of 
CVD among adults in LMIC. Several medical (PubMed, EMBASE, SCOPUS, Web of Science) and economic (EconLit, NHS 
EED) databases and grey literature were searched. Screening of studies and data extraction was done independently 
by two reviewers. Drummond’s checklist and the National Institute for Health and Care Excellence quality rating scale 
were used in the quality appraisal for all studies used to inform this evidence synthesis.
Results: From a pool of 4059 records, 94 full texts were read and 50 studies, which met our inclusion criteria, were 
retained for our narrative synthesis. Most of the studies were from middle‑income countries and predominantly of 
high quality. The majority were modelled evaluations, and there was significant heterogeneity in methods. Primary 
prevention studies dominated secondary prevention. Most of the economic evaluations were performed for phar‑
macological interventions focusing on blood pressure, cholesterol lowering and antiplatelet aggregants. The greatest 
majority were cost‑effective. Compared to individual‑based interventions, population‑based interventions were few 
and mostly targeted reduction in sodium intake and tobacco control strategies. These were very cost‑effective with 
many being cost‑saving.
Conclusions: This evidence synthesis provides a contemporary update on interventions that offer good value for 
money in LMICs. Population‑based interventions especially those targeting reduction in salt intake and tobacco 
control are very cost‑effective in LMICs with potential to generate economic gains that can be reinvested to improve 
health and/or other sectors. While this evidence is relevant for policy across these regions, decision makers should 
additionally take into account other multi‑sectoral perspectives, including considerations in budget impact, fairness, 
affordability and implementation while setting priorities for resource allocation.
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Background
Cardiovascular disease (CVD) is the number one 
cause of mortality globally, accounting for about 31% 
of worldwide deaths. Estimates from the Global Bur-
den of Disease (GBD) 2015 study showed that there 
were 422 million cases of CVD globally, and deaths 
from CVD have increased from 12.6 million in 1990 
to 17.9 million in 2015 [1]. Over four-fifths of prema-
ture mortality (deaths before age 70  years) from non-
communicable disease (NCD) occurs in low-income 
and middle-income countries (LMICs), and over a third 
is caused by CVD [2]. While the trend (1990–2015) 
in age-standardized prevalence of CVD is declining 
in high-income countries (HIC), this is not very obvi-
ous for most LMICs, where current rates are > 9000 
prevalent cases per 100,000 persons. Likewise, there 
have been significant declining trends in age-standard-
ized CVD mortality rates in all HICs, however similar 
changes have not been observed for the majority of 
sub-Saharan Africa and Southeast Asia [1].
The epidemiologic transition and demographic 
changes (population growth and ageing) have con-
tributed to the CVD burden in LMICs. Evidence from 
research on early life (in utero) exposures, genes, 
and the environment have added to the understand-
ing of the development and occurrence of CVDs 
in adulthood. Furthermore, metabolic (high blood 
pressure, high blood glucose, dyslipidemias, obesity) 
and behavioural (tobacco use, unhealthy diet, physi-
cal inactivity) risk factors are time-honored drivers 
fueling this CVD epidemic around the world [3]. A 
number of these risk factors are modifiable, and are 
targeted to curtail this burden via preventive and or 
treatment strategies.
There are several models of prevention, including 
population-wide and individual approaches targeting 
either individual risk factors, or multiple risk factors 
[4]. These strategies may be geared towards individu-
als with risk factors to prevent incidence of CVD events 
like cerebrovascular accidents and ischaemic heart dis-
ease (primary prevention) or in those with CVD events 
to prevent recurrence (secondary prevention) or reduce 
long-term impairment and disability resulting from a 
CVD event (tertiary prevention) [4]. Preventive inter-
ventions include (but are not limited to) medical proce-
dures, pharmacological (blood pressure and cholesterol 
lowering medication, anti-platelet aggregants, throm-
bolytic agents) and non-pharmacological (health edu-
cation, taxation, legislation) interventions.
Recognizing the plethora of individual country 
healthcare needs, and ever limited resources, the requi-
site for economic evaluation of interventions has been 
increasingly acknowledged [5]. This economic evidence 
forms one of the parameters for government and health 
policy makers as they decide on where to invest [6].
While there is overwhelming evidence in HICs from 
economic evaluations on the cost-effectiveness of inter-
ventions for CVD prevention, this is not the case for 
LMICs. Moreover, the transferability and implementa-
tion of interventions trailed in HIC to LMICs is debatable 
[7]. Among others, there are differences in effectiveness 
and cost related to variations in socio-cultural, environ-
mental, demographic, disease profiles and importantly, 
human and financial resources. Especially in Africa, 
LMICs are not only faced with the growing NCD burden, 
but are also afflicted by still-large burdens of infectious 
disease, nutritional disorders, neonatal and maternal 
mortality [8]. Thus, considering the inherent limited 
financial resources amidst these colossal health needs 
(communicable and non-communicable), their govern-
ments are faced with a greater challenge in choosing 
interventions that offer good value for money.
Based on the above, there is great need for robust 
evidence on which interventions are cost-effective to 
inform policy decisions. We must acknowledge that 
this is not the first review on economic evaluations for 
CVD. Suhrcke et  al. [7] and Shroufi et  al. [9] have pre-
viously reviewed the topic, though their work included 
studies only up to 2009 and 2010, respectively. The study 
by Suhrcke and colleagues had a number of limitations. 
While they used a reasonably sensitive database search 
strategy, they did not assess grey literature and so it is 
likely that they might have missed some important stud-
ies. Also, their quality assessment was based on authors’ 
statements on methods, instead of objective quality 
assessment tools. Furthermore, it is unclear why the 
study by Shroufi et al. included few studies. However, we 
noticed that in terms of geography, they used continen-
tal or regional names in their search. Including specific 
country names would likely have increased the sensitivity 
of their search strategy in capturing more studies.
Considering the time since the conduct of these stud-
ies and the above shortcomings, there is a clear need to 
provide updated and contemporary evidence of interven-
tions providing the most health gains with minimal costs, 
in the prevention CVD in LMICs.
Methods
This systematic review has been reported in accord-
ance with the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines [10], 
(Additional file  1). Our review was registered in the 
PROSPERO International prospective register of system-
atic reviews (registration number: CRD42016043510) at 
the Centre for Reviews and Dissemination, University of 
York, UK and the protocol has been published [11].
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Objective
The objective of this study was to identify, via a com-
prehensive synthesis, those interventions that are cost-
effective in the prevention of cardiovascular diseases 
in low-income and middle-income countries in order 
to inform and guide health policy in these countries in 
curbing the growing CVD burden.
Criteria for eligibility
For inclusion in this review, studies had to be primary 
(observational studies and randomized control trials) 
or modelling studies reporting on interventions for pri-
mary or secondary prevention of CVD among adults 
(> 18 years) from LMICs. Only those reporting full eco-
nomic evaluations (cost-effectiveness analysis (CEA), 
cost-utility analysis (CUA) or cost–benefit analysis 
(CBA)) with clear identification of comparators (either 
current practice or the ‘do nothing’ scenario) and out-
come measures such as cost per life year gained or per 
unit clinical outcome, cost per quality adjusted life year 
(QALY) or cost per disability adjusted life year (DALY) 
were considered. All studies written in English or 
French were included. We excluded narrative reviews, 
letters to the editor, case series with sample size less 
than 50 participants, and others lacking explicit infor-
mation on methods.
Data sources and search strategy
We conducted a comprehensive search of several medical 
and economic literature databases from inception to 10 
July 2017 (date of last search). Databases searched were: 
MEDLINE via PubMed, EMBASE, SCOPUS, Web of Sci-
ence, EconLit (American Economic Association), NHS 
Economic Evaluation Database (NHS EED) and Database 
of Abstracts of Reviews of Effects (DARE) via Centre for 
Reviews and Dissemination (CRD) database. The WHO 
AFROLIB, African Journals Online (AJOL) and Africa 
Index Medicus were also searched for literature specific to 
Africa. Additional file 2 shows in detail the search strategy 
which was adapted for each of the searched databases.
For grey literature, we searched websites of research 
organizations such as Disease Control Priorities (DCP) 
and WHO-CHOICE. We also searched Google Scholar 
and where necessary, corresponding authors were con-
tacted via email.
To further complement our database search, we 
perused the reference lists of the previous review stud-
ies and articles that met our inclusion criteria.
Screening and data extraction
Two reviewers independently screened titles/abstracts 
(LNA and BZ-D), independently screened full texts and 
extracted data (LNA and NTF) for studies included 
in the review. Any disagreements or conflicts were 
resolved by consensus or consultation with third 
reviewer (JLV).
Using a preconceived data-extraction form, all relevant 
data was obtained including first author name and year 
of publication, study setting, geographic region, country 
income level (according to 2017 World Bank classifica-
tion) [12], study design, intervention type and measure, 
intervention target, risk factor(s) examined, effect esti-
mate (relative risk or effectiveness measure), type of 
economic evaluation, comparator, outcome, type of sen-
sitivity analysis, economic perspective, incremental cost-
effectiveness ratio (ICER), cost-effectiveness as described 
by authors and the criteria, funding sources. For mod-
elling studies, the type of modelling strategy (micro- or 
macro-simulation), time horizon and discount rate were 
recorded while for primary studies, the specific study 
design, sample size of intervention and control groups, 
mean age of participants, percentage of male or female 
participants and length of follow-up data were obtained.
Quality assessment and appraisal
The reporting and methodological quality of all included 
studies was independently assessed by two review-
ers (LNA and NFT) using the Drummond checklist for 
economic evaluation studies [13]. This checklist has 35 
questions in total distributed under three major sections 
covering aspects of study design; sources and quality of 
data collected; data analysis and interpretation of results. 
These questions have Yes, No, Not clear and Not applica-
ble as possible responses (see Additional file 3). We then 
used the NICE scale in rating quality, with ‘++’ for good 
quality, ‘+’ for moderate quality, and ‘−’ for poor qual-
ity studies denoting low, moderate and high risk of bias, 
respectively [14]. The quality assessment was for overall 
study level and not the outcomes for included studies. 
Discrepancies in quality assessment were resolved by 
consensus.
Data management and synthesis
This has been previously described in the review protocol 
[11]. Briefly, EndNote V.7.4 software was used for removal 
of duplicate records. The remaining studies uploaded into 
Rayyan QCRI [15], which is a web and mobile-app inter-
net-based program that assists collaboration between 
reviewers through the screening and selection pro-
cess. All data extracted from final included studies were 
entered to Microsoft Excel 2013 spreadsheet. Data syn-
thesis involved stratifying and summarizing the evidence 
by preventive intervention type, appraising the economic 
evaluation methods used for assessing interventions and 
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presentation of cost-effectiveness outcomes. Inter-rater 
reliability for study inclusion and quality assessment was 
assessed using Cohen’s kappa coefficient (k). All analyses 
were done using STATA v. 15 (STATA corp, Texas, USA).
Results
Review search results
The database search yielded 4049 entries, and ten addi-
tional studies were obtained from the reference lists of 
prior reviews [7, 9] giving a total of 4059 studies. After 
removal of duplicates, 3016 studies were left. The titles 
and abstracts of these studies were screened indepen-
dently by two reviewers (LNA and BZ-D) for relevance. 
After exclusion of clearly irrelevant articles, 94 poten-
tially eligible articles remained which were then read in 
detail independently by two reviewers (LNA and NFT). 
Of these, 50 met our inclusion criteria. Data extraction 
and quality assessment was done by two independent 
reviewers (LNA and NFT). Inter-rater reliability (Kappa 
statistic) for study inclusion was high (k = 0.89). Figure 1 
shows the PRISMA flow diagram of the study selection 
process.
General characteristics of included studies
Included studies were published from the year 2000, with 
numbers progressively increasing (Fig. 2). Forty-four (88%) 
of these studies were from single countries, and six (12%) 
conducted for two or more countries. Most included studies 
were conducted for East Asia and the Pacific (n = 16, 32%), 
Latin America and the Caribbeans (n = 10, 20%), and sub-
Saharan Africa (n = 8, 16%), six (12%) studies where from 
multiple regions. The majority of studies were conducted for 
upper middle (n = 31, 62%) and lower middle (n = 10, 20%) 
income countries. Only three studies were conducted in 
low-income countries [16–18].
In 22 (44%) studies, the main focus was primary 
prevention while 18 (36%) were on secondary preven-
tion. Four were economic evaluations of hyperten-
sion or CVD screening [19–22]. The majority (n = 32, 
64%) of studies were pharmacological interventions, 
Fig. 1 PRISMA flow diagram
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followed by a mix of health education/promotion, leg-
islative and medical procedure interventions. Most 
interventions targeted individuals (n = 38, 76%) with 
only seven for population-based interventions [20, 
22–27], and five studies including both individual and 
population-based strategies [28–32]. Among CVD 
risk factors, twenty studies looked at interventions for 
single risk factors, on high blood pressure (BP) alone 
(n = 13, 38.2%), followed by high cholesterol (n = 3, 
8.8%), atrial fibrillation (n = 2, 5.9%), salt (n = 1, 2.9%) 
and tobacco (n = 1, 2.9%). Fourteen (41.1%) studies 
assessed multiple risk factors including varied com-
binations of BP, cholesterol, smoking and salt intake; 
13 of which assessed absolute CVD risk [16–18, 26, 
28–36], with one comparing CVD risk in those with 
and without diabetes [17]. Two (5.9%) studies were in 
persons with atrial fibrillation [37, 38]. Details of study 
characteristics are shown in Table 1.
Quality appraisal
Half of the included studies were of high quality. Of 
the remaining studies, 21 (42%) classified as moderate 
quality and 4 (8%) as low quality. Details of the qual-
ity assessment can be found on Table 2 and Additional 
file 4.
Evidence on interventions and their cost‑effectiveness
Primary prevention
All but four studies evaluating legislative or health educa-
tion interventions [24, 25, 33, 34], focused on pharmaco-
logical interventions. Most of them targeted individuals, 
with just two exclusive population-based [24, 25] and 
three targeting both individuals and populations [29, 31, 
32].
Blood pressure lowering interventions Among stud-
ies that evaluated the cost-effectiveness of single anti-
hypertensive drugs, diuretics were found to be the most 
cost-effective; for initiation as monotherapy [35], for use 
in high risk groups [16], and at various absolute CVD risk 
levels [36]. Other BP-lowering medication had compara-
tively higher cost-effectiveness ratios or were cost-inef-
fective [16, 18, 35, 36] except for Candesartan, which was 
found to be cost-effective compared to other Angiotensin 
II receptor blockers in South Africa [37].
In studies evaluating combination therapies, most 
were generally dominant or cost-effective in all tested 
[38] or some [18, 28, 31, 39, 40] absolute CVD risk 
thresholds, and in people with SBP > 160  mmHg [29]. 
In people with diabetes, apart from ACE inhibitors and 
CCB combinations in low and moderate CVD risk indi-
viduals, other BP lowering drug combinations were not 
cost-effective in Tanzania [17]. Three studies assessed 
cost-effectiveness of various BP treatment guidelines/
strategies. In one, treatment based on the 10-year abso-
lute CVD risk was cost effective, whereas treatments 
based on SBP levels of > 140 or > 160  mmHg were not 
cost-effective [41]. A modelled evaluation compared 
three BP treatment strategies; treatment to target 
(TTT), benefit-based tailored treatment (BTT) and 
a hybrid strategy proposed by the WHO. The authors 
found that BTT was more cost-effective than TTT or 
the hybrid strategy [42]. Gu et al. found that treatment 
Fig. 2 Publication trends by year
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of individuals with stage 2 hypertension only or those 
with either stage 1 or stage 2 using low cost anti-hyper-
tensives were cost-effective [43]. In a RCT comparing 
the impact of home health education alone, GP training 
alone, or the combination of both versus usual care in 
reducing SBP, the combination strategy was most cost-
effective [33].
Cholesterol lowering interventions Individual drug treat-
ment with statins was found to be dominant at both LDL 
cholesterol thresholds of 160 and 190 mg/dL [44], highly 
cost-effective in Iranian men older than 44 years [45] and 
cost-effective at various CVD risk thresholds [17, 28, 31, 
32]. In Vietnam, individual statin treatment for choles-
terol levels > 5.7 mmol/L and > 6.2 mmol/L was cost-effec-
tive, though less attractive compared to other measures 
explored [29]. At same cholesterol levels, statin treatment 
was not cost-effective in Kyrgyzstan [26]. When statin 
was added to a combination of BP lowering medications, 
it was found to considerably increase ICERs in Thailand 
[38]. In one study in Tanzania, individual statin treatment 
alone or in combination with BP-lowering medication 
and aspirin in all absolute CVD risk thresholds was not 
cost effective [16]. At population level, mass media and 
health education interventions for reducing cholesterol 
were found to be cost-effective [29, 32].
Polypill interventions Three studies evaluated treat-
ment with the polypill in Latin American countries [46], 
Thailand [38] and Argentina [31]. In the study among 
Latin Americans, the polypill consisted of a combina-
tion of three anti-hypertensives (thiazide 12.5 mg, ate-
nolol 50 mg, ramipril 5 mg), statin (simvastatin 20 mg) 
and aspirin 100  mg administered once daily to high 
risk individuals compared to no polypill. It was found 
to be cost-effective in high risk women and for men 
aged ≥ 55 years [46]. In Argentina, the polypill strategy 
comprised administering a combination of enalapril 
10 mg, hydrochlorothiazide 25 mg, atorvastatin 10 mg 
and aspirin 100 mg to people at various absolute CVD 
Table 2 Quality assessment of  studies with  Drummond’s 
checklist and UK National Institute for Health and Clinical 
Excellence (NICE) quality criteria




Permanicha et al. 2015 24/35 + Moderate
Anderson et al. 2000 15/35 − High
Mason et al. 2014 29/35 ++ Low
Donaldson et al. 2011 25/35 + Moderate
Yan et al. 2015 17/35 − High
Bautista et al. 2013 24/35 + Moderate
Anderson et al. 2000 21/35 + Moderate
Basu et al. 2016 29/35 ++ Low
Khonputsa et al. 2012 28/35 ++ Low
Rabus et al. 2005 22/35 + Moderate
Gaziano et al. 2006 27/35 ++ Low
Gaziano et al. 2015 26/35 + Moderate
Li et al. 2015 31/35 ++ Low
Ortegon et al. 2012 29/35 ++ Low
Permsuwan et al. 2015 28/35 ++ Low
Ha et al. 2011 30/35 ++ Low
Schulman‑Marcus et al. 
2010
28/35 ++ Low
Jafar et al. 2011 29/35 ++ Low
Choosakulchart et al. 2013 28/35 ++ Low
Lakic et al. 2012 20/35 + Moderate
Pan et al. 2014 29/35 ++ Low
Wilcox et al. 2015 26/35 + Moderate
Gaziano et al. 2005 27/35 ++ Low
Amirsadri and Hassani 
2015
31/35 ++ Low
Wu et al. 2014 28/35 ++ Low
Mejia et al. 2015 25/35 + Moderate
Salomon et al. 2012 27/35 ++ Low
Gu et al. 2015 29/35 ++ Low
Nguyen et al. 2016 29/35 ++ Low
Davies et al. 2013 24/35 + Moderate
Jarungsuccess et al. 2014 23/35 + Moderate
Wang et al. 2013 23/35 + Moderate
Robberstad et al. 2007 26/35 + Moderate
Ngalesoni FN et al. 2016 28/35 ++ Low
Tolla et al. 2016 27/35 ++ Low
Rubinstein et al. 2010 27/35 ++ Low
Basu et al. 2015 26/35 + Moderate
Rosendaal et al. 2010 28/35 ++ Low
Ekwunife et al. 2013 27/35 ++ Low
Amirsadri and Sedighi 
2017
29/35 ++ Low
Wang et al. 2017 15/35 − High
Polanczyk et al. 2007 22/35 + Moderate
Garcia‑Pena et al. 2002 21/35 + Moderate
Ribeiro et al. 2010 28/35 ++ Low
Drummond summary score: ≥ 27/35 (75%) = ‘++’, 18–26/35 (50–75%) = ‘+’, 
score < 18/35 (< 50%) = ‘−’
Table 2 (continued)




Araujo et al. 2008 21/35 + Moderate
Araujo et al. 2007 24/35 + Moderate
Murray et al. 2003 25/35 + Moderate
Akkazieva et al. 2009 21/35 + Moderate
Gonzalez‑Diaz et al. 2015 26/35 + Moderate
Huang and Ren 2010 13/35 − High
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risk levels. This was cost-effective in those with a 10 year 
CVD risk of ≥ 20% [31]. Finally, in the Thai study, a theo-
retical polypill intervention was used which consisted of 
a statin in full dose and three anti-hypertensives (diu-
retic, calcium channel blocker and ACE inhibitor) in 
half standard doses versus a do nothing scenario. This 
intervention was cost-saving in all 10  year CVD risk 
threshold levels, surpassing combination with 3 indi-
vidual anti-hypertensive drugs [38].
Smoking control interventions As regards smoking 
control interventions, most studies explored popula-
tion-based strategies, including mass media campaigns 
[26, 28, 29, 31], legislation for smoking bans [24, 28] 
and increased taxation [28, 30]. Implementing a com-
plete smoking ban compared to a partial smoking ban 
was cost-saving in India [24], while all mass media 
campaigns against smoking and increased taxation for 
tobacco products were cost-effective [28–31]. However, 
in Mexico, smoking ban and clean indoor air laws were 
found not to be cost-effective [30]. In the three studies 
that evaluated individual-level tobacco interventions, 
treatments with Bupropion [30] and nicotine replace-
ment therapy [28, 31] were found not to be cost-effective.
Salt intake reduction interventions All interventions 
to reduce salt intake were population-based, and exam-
ined health education via mass media campaigns [23, 
25, 26, 28, 29], reduction of sodium content in bread 
[31], or voluntary industry labelling of foods and man-
datory reformulation [23, 25, 28, 30, 32]. All health edu-
cation strategies were found to be cost-effective. The 
reduction of sodium content in bread was cost-saving; 
product reformulation and voluntary reduction were 
similarly cost-effective or cost-saving, especially when 
implemented in combination.
Atrial fibrillation Two studies assessed the use of oral 
anti-coagulants in adults with atrial fibrillation (AF) for 
primary prevention of stroke. In Thailand [47], three 
new oral anticoagulants (rivaroxaban, apixaban, and 
dabigatran) were compared with warfarin in adults aged 
65 years and above with non-valvular AF while in China 
[48], rivaroxaban was compared with warfarin, aspirin, 
aspirin with clopidogrel and no prevention in adults 
with AF stratified into seven CHADS2 score categories. 
In both studies, the new oral anticoagulants were not 
cost-effective.
Secondary prevention
Interventions here were predominantly pharmacologi-
cal, covering single or combination therapies for blood 
pressure and cholesterol, anti-platelet aggregates, anti-
coagulants and thrombolytic therapy in patients with 
CVD events (myocardial infarction (MI), stroke, heart 
failure). One study investigated the cost-effectiveness 
of influenza vaccination in those with ischaemic heart 
disease. The rest of the studies focused on medical pro-
cedures (stents, implantable cardioverter defibrillators 
(ICD), percutaneous coronary interventions (PCI)).
Blood pressure, cholesterol lowering and  antiplatelet 
aggregate interventions Among studies that evaluated 
treatment with blood pressure lowering medication only, 
ACE inhibitors [49] and diuretics [30] were found to be 
cost-effective or cost-saving [43]. However, other single 
treatment interventions with beta-blockers and statins 
were not cost-effective [18, 28, 30]. One study assessed 
the addition of n-3 polyunsaturated fatty acids to stand-
ard therapy in post MI patients for secondary CVD pre-
vention and mortality, and it was not cost-effective [50]. 
Combination therapies with a range of BP lowering drugs, 
statin and aspirin were found to be cost-effective in pre-
venting recurrent stroke events, MI or both [18, 40, 51]. 
However, Tolla and colleagues found that in Tanzania, 
some selected combinations of BP and cholesterol lower-
ing drugs with aspirin were not cost-effective [18].
Five studies specifically evaluated the cost-effectiveness 
of antiplatelet drugs. Two of them showed that clopi-
dogrel alone [52] and clopidogrel with aspirin [53] were 
more cost-effective than aspirin alone. In one study, 
clopidogrel for secondary prevention of stroke was cost-
ineffective [51]. Ticagrelor was also more cost-effective 
than clopidogrel in patients with acute coronary syn-
dromes in preventing future stroke or MI [54]. In acute 
coronary syndrome patients undergoing percutaneous 
interventions, prasugrel was cost-effective in reducing 
risk of mortality, stroke and MI [55].
Anticoagulant and  thrombolysis interventions Seven 
studies evaluated interventions with anticoagulant or 
thrombolytic therapies. Tissue plasminogen activator 
was found to be cost-effective, when used within 6 h of 
ischemic stroke [56] and when compared to Streptokinase 
[57]. In one study, prehospital thrombolysis was found to 
be cost-effective compared to in-hospital use [58]. Strep-
tokinase was moderately cost-effective when used in com-
bination with other BP medication [18, 51], but not cost-
effective when used alone [26]. In one study, fondaparinux 
was found to be cost-saving compared to enoxaparin in 
patients with non-ST segment elevated MI (NSTEMI) 
acute coronary syndrome [59].
Medical procedures Four studies evaluated procedures 
including, PCI [51], stents [60, 61] and ICD [62]. For 
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stents, drug-eluting early generation and new generation 
stents were cost-effective compared to bare metal stents 
[61]. In Brazil, though stents were not cost-effective in 
preventing CVD events, a sensitivity analysis showed 
favourable ICERs in patients with diabetes and for small 
vessels needing revascularization [60]. Compared to 
standard heart failure (HF) therapy, ICD use in those aged 
60 years with HF was not cost-effective in Brazil [62]. In 
China, PCI was not cost-effective in high-risk patients 
with NSTEMI acute MI [51].
Screening interventions
Three studies evaluated hypertension-screening strat-
egies for population-based interventions [20, 22] and 
individual/high risk individuals [19]. In Nigeria, two 
strategies were compared to no screening; strategy 1 
entailed hypertension screening and treatment for those 
with stage 1 hypertension (SBP = 140–159  mmHg and/
or DBP = 90–99  mmHg) combined with 10-year CVD 
risk < 20% or stage 2 hypertension (SBP ≥ 160  mmHg 
and/or DBP ≥ 100 mmHg) with any CVD risk level. Strat-
egy 2 entailed screening and treatment of all hyperten-
sive people with CVD risk > 20%. The second strategy 
was found to be cost-effective while strategy 1 was only 
moderately cost-effective with a tendency to be domi-
nated [22]. In Vietnam, four screening scenarios (one-off 
screening, annual screening, screening every 2 years and 
screening in combination with increased treatment cov-
erage) were modelled. All scenarios were cost-effective 
for men. However, for women two-yearly screening and 
screening at 35 years were not cost-effective [20]. Gazi-
ano et  al. evaluated paper-based and mobile app based 
CVD screening by community health workers com-
pared to standard care (opportunistic screening). The 
mobile app was cost effective in Mexico and Guatemala 
and cost-saving in South Africa [19]. One study in India 
evaluated the cost-effectiveness of general practitioners 
doing pre-hospital electrocardiograph (ECG) in patients 
with chest pain for diagnosis of acute coronary syndrome 
prior to referral, compared to no ECG. They found that 
this was a very cost-effective strategy estimated at US$13 
per QALY gained [21].
Methods used in economic evaluation
Table  3 summarizes the methods used in the included 
studies. Overall, cost-utility analysis was most frequently 
used (n = 29, 58%), followed by cost-effectiveness analysis 
(n = 14, 28%). Six studies used both CUA and CEA [37, 
45, 50, 52, 62, 63]. There was only one cost–benefit analy-
sis [27]. Overall, among the 20 studies which did CEA, life 
years gained/saved was the predominant benefit measure 
[23–25, 41, 44, 45, 49, 50, 52, 57, 58, 62, 63], while the rest 
of the studies either used drop in blood pressure [33, 34, 
37, 39], avoided CVD [24, 44, 61] or restenosis [60] event 
as benefit measure. Out of 38 studies that mentioned 
their approach to defining an intervention as cost-effec-
tive or not, 7 employed the willingness to pay threshold, 
while the majority (n = 31) used the WHO’s Commission 
on Macroeconomics and Health (CMH) threshold using 
the respective countries’ GDP per capita.
Overall, 43 studies were modelled economic evalua-
tions, while seven were empirical studies with three eco-
nomic evaluations conducted with randomized trials [33, 
34, 39] and four alongside observational studies [27, 56, 
57, 61]. For the modelling studies, the majority used a 
macrosimulation approach, mostly Markov models, with 
three incorporating decision trees [20, 59, 60]. Among 
the five studies that used microsimulations, two specifi-
cally used discrete-event simulation [52, 64] while the 
others [19, 42, 48] did not state the technique used.
With respect to study time horizon, 27 studies evalu-
ated interventions over the lifetime of the study popula-
tion. Six studies did not state the time horizon [27, 33, 
34, 39, 56, 61] while the remaining studies (n = 17) varied 
from one to 30 years.
The majority of studies used a healthcare perspective. 
A societal perspective was used in 12 studies; however 
in eight, there was no estimation of productivity loss [17, 
21, 24, 30, 40, 47, 51, 64]. Two studies used the third party 
payer perspective [35, 36], one used the patient perspec-
tive [34] and two did not state their perspective [26, 32].
As regards discounting, 40 out of the 50 used discount-
ing for cost and outcomes, most (n = 37) used 3% as their 
discounting factor. Two of them used 5% [33, 35] and one 
used 7% [44].
Uncertainty analysis was performed in 40 studies, with 
the majority doing deterministic (one-way) and proba-
bilistic sensitivity analysis. Ten studies did not state or 
incorporate any uncertainty around their ICER estimates 
[23, 24, 26, 27, 30, 37, 39, 44, 49, 58].
In all, 34 studies received some form of funding, 
including four cases that were funded by pharmaceutical 
companies [37, 52, 59, 60]. Seven studies did not receive 
funding while nine did not mention any funding details.
Discussion
The evidence on cost-effectiveness of interventions for 
CVD prevention is growing rapidly, with the majority 
of studies being modelled economic evaluations in the 
middle-income countries. Primary prevention studies 
outnumbered those for secondary prevention. Most eco-
nomic evaluations were for pharmacological interven-
tions focusing on blood pressure, cholesterol lowering 
and antiplatelet aggregants. BP lowering interventions 
(mostly diuretics and its combinations) were cost-effec-
tive, especially in high risk populations. While some 
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cholesterol lowering interventions alone were not cost-
effective, treatment interventions based on absolute CVD 
risk were mostly cost-effective, with the polypill being 
most economically attractive. Population-based interven-
tions were few and mostly targeted reduction in sodium 
intake and tobacco control strategies, and were usually 
cost-saving.
We observed that the number of publications on eco-
nomic evaluations for CVD prevention have steadily 
increased, especially during the last decade. This coin-
cides with, and might arguably be thanks to, the efforts 
of the Disease Control Priorities Project (DCP2) in 2006, 
which explored among others the cost-effectiveness 
of various interventions to combat NCDs. Addition-
ally, the earlier publication of the WHO guide to cost-
effectiveness analysis in 2003 [6], and availability of 
WHO-CHOICE methods [65] are likely catalysts for this 
observed surge in publications.
For primary prevention, the majority are pharmaco-
logical interventions and target high blood pressure, 
high cholesterol and antiplatelet therapy either singly 
or in combination. Individual strategies focusing on BP 
lowering therapies have shown that compared to other 
antihypertensive drug classes, diuretics are consistently 
the most cost-effective as monotherapy. Other classes 
like beta-blockers, ACE inhibitors and calcium chan-
nel blockers tend to be favourable mostly when used in 
combination. Individual treatments with statins are cost-
effective in some settings and are not in others, in part 
due to the different statin drugs evaluated with differing 
prices across countries. Studies that have evaluated the 
hypothetical polypill show that it is a very cost-effective 
option. However, controversy still looms as regards large 
scale implementation especially in relation to conse-
quences/side-effects of mass treatments and stretching of 
limited budgets in LMICs [7].
Secondary prevention strategies are similarly geared 
towards pharmacological strategies, and besides blood 
pressure and cholesterol lowering interventions; there 
has also been some focus on thrombolysis and medical 
procedures. Pharmacological interventions are mostly 
cost-effective, though with some specifics worth consid-
ering. Population-based interventions are relatively few 
but are cost-effective and or cost-saving. Differences in 
demographics and epidemiology, modelling assump-
tions, intervention costs and effectiveness across settings, 
economic perspectives and time horizons for which 
interventions are assessed and variation in compliance 
levels, likely account for the dissimilar conclusions across 
studies.
Other individual strategies to control smoking like 
treatments with Bupropion and nicotine replacement 
therapy are not cost-effective options in the LMICs, 
although some reports from HICs have shown promise 
[66].
Population-based interventions have mostly focused 
on reduction in salt (sodium) intake and smoking. These 
appear to be the most attractive population-wide inter-
ventions, being either very cost-effective or cost-saving 
in CVD prevention. In a recent systematic review, Hope 
and colleagues [67] summarized the evidence on eco-
nomic evaluations of population-based sodium reduction 
interventions. Similar to our findings, they highlighted 
that salt reduction interventions offer good value for 
money. However, similar to ours, they noted that there 
are few studies assessing the impact of salt tax legislation 
[67]. Most of the salt reduction interventions focused 
on health education via mass media campaigns, product 
reformulation and relabeling.
With respect to tobacco smoking control strategies, 
contrary to a previous review [66] that suggested major-
ity of interventions focused on nicotine replacement 
therapy (NRT) and self-help therapies, we found that 
mass media campaigns, increasing taxes and smoke-
free laws were the predominant interventions studied. It 
is likely that the search strategy and comparatively lim-
ited number of databases searched in the prior review, 
coupled with a focus on high-income countries, might 
explain the difference. It should be noted, however that 
we found no economic evaluations of school-based ces-
sation programs, smoking quitlines and tobacco control 
programs in pregnant women, which have been shown 
to be cost-effective and potentially cost-saving elsewhere 
[68–70]. The absence of such economic evidence might 
be due to the non-existence of such programs or studies 
evaluating them in LMICs. This constitutes a gap in the 
strategies to tackle the tobacco epidemic.
With respect to medical procedures, we found very few 
studies have assessed their cost-effectiveness in LMICs, 
with the available studies mostly done in Latin American 
countries. In Brazil for example, early and new generation 
stents were considered cost-effective, though with limited 
benefit for moving from early to the new generation stents. 
Considering the limited available evidence here and the 
fact that many other regions have not evaluated the use of 
stents and ICDs, it is difficult to draw reasonable conclu-
sions. However, on a case by case basis, clinicians will be 
required to strike a balance between long term clinical effi-
cacy and costs to patients and health system.
Screening strategies have been less well explored com-
pared to other interventions. The few existing studies 
suggest that some strategies are potentially cost-effective. 
In a bid to enhance their economic attractiveness, their 
implementation must be stratified for specific population 
age groups and gender, as well as tailored to account for 
countries’ specific needs.
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As observed in previous reviews [7, 9], there are 
still few economic evaluations of interventions target-
ing other risk factors like physical activity, alcohol con-
sumption and body mass. These are established drivers 
for CVD, and it is important that future studies should 
consider evaluating interventions targeting those drivers, 
so as to provide broad perspectives for consideration in 
stemming the CVD burden.
The majority of included studies are modelled evalu-
ations, with the majority using Markov modelling. This 
modelling approach has been widely discussed to be 
suited in modelling chronic diseases such as cardiovas-
cular disease [71]. While model-based evaluations might 
not be same as real life situations, they are increasingly 
gaining place in economic evaluation, for a number of 
reasons. Firstly, economic evaluations conducted along-
side RCTs are likely to be limited in time horizon as it is 
costly for trials to extend for several years [72]. Secondly, 
the majority of RCTs have intermediate endpoints (such 
as change in BP or change in cholesterol) as their out-
come and very few extend to final end points (CVD event 
or death, let alone QALYs or DALYs). As such, these are 
unlikely to reveal the complete picture of costs and ben-
efits of an intervention. Model-based evaluations have 
the potential to address these problems by using long 
time horizons [72]. This is particularly seen for smoking-
related interventions whose benefits generally accrue 
in the fourth or fifth decades following implementation 
of the intervention [73]. Contrary to previous reviews, 
which found no cost–benefit analysis, we found a sin-
gle study using this evaluation method. While there is 
clearly a dearth in studies using this method for evalua-
tion, cost–benefit analyses are likely to be also relevant to 
policy makers as it allows for direct comparison of health 
interventions with interventions in other sectors [13].
Up to one-fifth of included studies either did not assess, 
or failed to incorporate, uncertainty around their ICER 
estimates. This is particular, as most of the parameters 
used in modelling studies come from multiple sources, 
from contexts that differ from those of the target popula-
tion. It is important to determine the uncertainty around 
the benefits and costs, and how this affects the ICER 
estimates. The uncertainty around the cost-effectiveness 
of interventions is important for policy makers, as they 
broadly assess and compare the potential gains or losses 
from implementing one intervention over another [74].
About two-thirds of included studies received some 
form of funding, mostly from government ministries 
and universities or educational institutes. We noted that 
four studies were funded by pharmaceutical industries. 
Lundh and colleagues in a Cochrane review discussed 
the impacts of industry funding on research outcomes, in 
which they highlight that most industry-funded trials are 
likely to report drugs as efficacious or less harmful [75]. 
This bias is similarly likely to occur in economic evalu-
ation studies, with such [industry-funded] studies likely 
to report an intervention or drug as being cost-effective. 
It is difficult to say with certainty the accuracy of conclu-
sions drawn from the four studies in our review which 
received pharmaceutical industry funding; with two hav-
ing low risk of bias [52, 59] and two of moderate risk [37, 
60]. It is possible that eliminating these studies, especially 
those with moderate risk may potentially influence some 
of our conclusions. We again highlight that interpretation 
of such findings should be done with caution.
As regards methods for defining an intervention as 
cost-effective or not, the majority of studies used the 
WHO Commission on Macroeconomics and Health 
approach of multiples of GDP per capita, and only very 
few used a priori willingness-to-pay thresholds. While 
the proposed WHO method is good at determining 
those interventions that have good or very good value 
for money, Bertram and colleagues recently argued about 
the misuse of these thresholds for decision-making [76]. 
Modelled cost-effectiveness ratios are amongst others 
dependent on the construct and validity of the models, 
variable sources of input parameters; they suggest that 
for priority setting, decision makers should, besides 
cost-effectiveness thresholds, take into account other 
factors such as budget impact, affordability, feasibility 
of implementation and fairness [76]. Similarly, Remme 
and co-workers have recently proposed a multi-sectoral 
perspective for resource allocation, arguing that multiple 
sectors potentially contribute to health gain and that the 
goods and services obtained from health sector or inter-
ventions can have multiple benefits outside health [77].
In a number of LMICs, Health Technology Assess-
ment (HTA) is currently being considered to guide pol-
icy makers in priority setting for the allocation of scarce 
resources. Over the last decade, NICE International and 
Thailand’s Health Intervention and Technology Assess-
ment Program (HITAP) agreed to create partnerships to 
improve priority setting in LMICs for HTA. Their efforts 
are well underway in Latin American and Asian coun-
tries like Colombia, Vietnam, India, Myanmar and the 
Philippines [78]. In Africa, some strides have been made 
in countries like Ghana and South Africa, however, there 
are still huge gaps including absence of dedicated HTA 
institutions and limited research capacity [79, 80]. While 
countries, especially those that have adopted universal 
health care (UHC) are pushing for HTA to assist them 
allocate resources appropriately and equitably, as they 
sustain the UHC programs, studies have suggested that 
local evidence to inform HTA is limited [81], and fur-
ther widens the gap between research and policy which 
is already challenged by low awareness and lack of will 
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among policymakers in the region. We believe our efforts 
in this review will be very beneficial for policymakers 
in two facets. First, to feed countries with existing HTA 
institutions with comprehensive local evidence on inter-
ventions that have good value for money as they identify 
where to invest and guide their HTA efforts. Secondly, 
our findings will contribute in narrowing the existing 
knowledge gap on cost-effectiveness on CVD preventive 
interventions, while highlighting the importance of eco-
nomic evaluations of interventions as an important guide 
to resource allocation and priority setting in LMICs with 
already strained financial resources.
Recommendations for policy and future research
To bridge the existing knowledge and evidence gap on 
cost-effectiveness research, and by extension improve 
the health of populations via provision of cost-effective 
preventive interventions, experts at the MOH and policy 
makers should consider; (i) research and capacity build-
ing and (ii) the creation of a conducive and enabling envi-
ronment for the generation of local quality research to 
inform decisions.
Building research capacity, that is, creation of institu-
tions for economic evaluation and improving techni-
cal capacity of local staff via training and workshops 
will empower local researchers with the skills necessary 
to generate more local and context-specific evidence 
to inform policy and decision-making on cost-effective 
strategies for disease prevention. Encouraging and facili-
tating partnerships and collaboration between other 
governments, organizations and researchers within and 
without the countries are other avenues for capacity 
building.
Policymakers in the first instance need to develop the 
political will and interest in cost-effectiveness research 
and acknowledge its contribution to priority-setting and 
resource allocation. By so doing, they are likely to more 
easily understand the funding needs of researchers and 
organizations, for the generation of the much needed 
high-quality local evidence. This is particularly impor-
tant as we note in our review that the evidence-base from 
LMICs especially the low-income countries is scant. 
Decisions based on evidence generated from HICs are 
unlikely to adequately address the needs of these popu-
lations due to differences in demographics, intervention 
effectiveness, variation in healthcare costs and standards 
of living, cultural differences all likely to affect acceptabil-
ity, implementation and affordability of interventions.
Taken together, there is a compelling need to link 
research and policy by improving the interaction between 
researchers and policymakers via policy meetings, dedi-
cated sessions at conferences where policy makers meet 
with researchers to discuss evidence, opinions and thus 
creating opportunities for researchers and their findings 
to be more actively involved in policy decisions.
In terms of future research, we note that majority (over 
two-thirds) of studies have focused on pharmacological 
interventions. Upcoming endeavours should consider 
looking into non-pharmacological (behavioural and life-
style) interventions. Secondly, there has been a focus 
on individual level interventions. Further research on 
population-level interventions especially those targeting 
risk factors like salt intake and smoking, and legislative 
interventions which have in most cases been shown to 
be very cost-effective and cost-saving are potential areas 
for focus. For risk factors, most studies have focused 
on blood pressure, cholesterol, and smoking. We found 
almost no studies on economic evaluations for reduction 
in alcohol consumption, physical inactivity, consumption 
of fruits and vegetables and weight control interventions. 
These risk factors carry significant burden in LMICs [82], 
and the limited available interventions for their con-
trol highlight important caveats in the literature from 
the LMICs that need to be explored in future research 
efforts. Finally, we believe there is need for further work 
in harmonization and transparence in research analytical 
methods especially for modelled economic evaluations, 
as drawing conclusions from such synthesis efforts from 
studies with largely heterogeneous methods requires a 
high degree of caution in interpretation of findings, as 
well as consideration towards transferability and imple-
mentation in other settings.
Strengths and limitations
This systematic review has some limitations that should 
be discussed. First, limiting our search to only articles 
in English and French, we might have potentially missed 
articles in other languages. We however developed a 
detailed and comprehensive search strategy, accessed 
multiple databases and grey literature which hopefully 
should have minimized our missing potential studies. 
Secondly, a meta-analysis was not done. This is however 
not surprising for systematic reviews of economic evalu-
ations, owing to the significant heterogeneity in applied 
methodologies, resources used and evidence on interven-
tion effectiveness. It is important to note that the role of 
systematic reviews of economic evidence is not just to 
generate a single summary answer as is generally with 
systematic reviews of RCTs [83]. The focus here is rather 
to provide policy/decision makers, clinicians, and stake-
holders with information on the variety and quality of 
available evidence on cost-effectiveness of given interven-
tions, relevant choices and or trade-offs they are likely to 
contend with, to identify gaps in the literature, and hope-
fully provide an understanding of the contexts and con-
ditions under which interventions may be cost-effective 
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[83]. Finally, among studies included, 50% were of high 
quality and further 40% being moderate quality. On the 
whole, we can therefore have a fair degree of confidence 
in our findings.
Conclusions
This systematic review has provided contemporary evi-
dence on the interventions that offer good value for money 
for the prevention of CVD in LMICs. The bulk of studies 
focused on pharmacological and other individual-level 
interventions, which often were found to be cost-effec-
tive. Population strategies, though under-represented in 
the evidence base, are similarly very attractive economi-
cally. The available evidence suggests that stemming the 
CVD epidemic in LMICs would require both individual 
and population-based strategies to achieve maximal 
health gains at lowest possible costs. Additionally, there 
is need for a focus on interventions to address other risk 
factors like physical inactivity, low fruits and vegetable 
consumption, alcohol intake and body mass. Decision 
makers must however not rely exclusively on cost-effec-
tiveness thresholds, but take into account multi-sectoral 
approaches, and other country and context-specific factors 
as budget impact, affordability, fairness and implementa-
tion as they contemplate which interventions to invest in. 
Finally, governments in LMICs need to strongly consider 
strengthening and building research capacity on economic 
evaluations of interventions, health technology assess-
ment, as well as bridging the gap between research and 
policy in order to make informed decisions for priority set-
ting towards the allocation of their scarce resources.
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